Hidradenitis Suppurativa Epidemiology Forecast - 2034
Description
Key Highlights
In 2024, there were around 1.8 million diagnosed prevalent cases of hidradenitis suppurativa in the 7MM, and this number is expected to grow over the forecast period.
Low disease awareness and associated misdiagnoses and under-reporting by patients because of shame and embarrassment have contributed to substantial delays in diagnosis, reported to be between 7 and 10 years on average. The course of the disease is often unpredictable, which can be challenging for patients and healthcare professionals (HCPs) in managing hidradenitis suppurativa.
According to secondary research, the widely reported prevalence rate is 0.03-4 percent. This disparity could be explained by differences in research design (for example, prospective vs. retrospective studies or registry-based vs. self-reported questionnaire-based studies).
Many hidradenitis suppurativa patients are often misdiagnosed and not at all diagnosed. Based on the analysis it is estimated that only 25–30% of patients receive the diagnosis of hidradenitis suppurativa.
The Gender-specific analysis suggests that hidradenitis suppurativa is more prevalent in females than males in the US and Europe but in Japan, it is more prevalent in males than females.
Data suggests that of the diagnosed patient pool, roughly 40%–50% of the hidradenitis suppurativa patients have moderate-to-severe disease in the US.
According to DelveInsight’s analysis, the highest proportion of hidradenitis suppurativa prevalent pool was observed in the 30–39 age group among the 7MM.
According to Hurley’s classification, hidradenitis suppurativa can be classified into stages, i.e., Stage I, II, and III. The most prevalent cases are estimated to be at Stage I.
DelveInsight’s “Hidradenitis Suppurativa – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Hidradenitis Suppurativa, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Hidradenitis Suppurativa Disease Understanding
Hidradenitis Suppurativa Overview
Hidradenitis suppurativa is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as acne inversa, and there is no biological or pathological test to facilitate diagnosis; its clinical features and chronicity can define it.
The underlying cause of hidradenitis suppurativa is unknown, but the condition probably results from genetic and environmental factors.
Hidradenitis Suppurativa Diagnosis
The diagnosis is primarily clinical, based on symptoms reported by the patient and signs observed by the physician. No pathognomonic test exists; a biopsy is rarely required, especially in well-developed lesions. Primary diagnosis of hidradenitis suppurativa involves identifying the disease and assessing its comorbidities.
Fulfillment of three criteria is necessary for the diagnosis of Hidradenitis suppurativa, which includes- typical lesions (deep-seated, painful nodules), characteristic distribution or typical anatomical predilection (i.e., axillae, groins, perineal and perianal regions, buttocks, infra-mammary and inter-mammary folds), and recurrence (Chronicity and recurrence of lesions). Arbitrarily, two recurrences over 6 months have been used as a qualifier for a diagnosis. All three criteria must be present for the definitive diagnosis. Smoking is a significant association, and cessation is important for disease control. Approximately one-third of patients with hidradenitis suppurativa have a family history of the disease.
Further details related to diagnosis are provided in the reported
Hidradenitis Suppurativa Epidemiology
As the market is derived using a patient-based model, the Hidradenitis Suppurativa epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of hidradenitis suppurativa, total diagnosed prevalent cases of hidradenitis suppurativa, gender-specific diagnosed prevalent cases of hidradenitis suppurativa, age-specific diagnosed prevalent cases of hidradenitis suppurativa, stage-specific diagnosed prevalent cases of hidradenitis suppurativa and total treated diagnosed prevalent cases of hidradenitis suppurativa in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
The total prevalent cases of hidradenitis suppurativa in the 7MM comprised approximately 6.3 million cases in 2024 and are projected to increase during the forecast period.
In 2024, the total diagnosed prevalent cases of Hidradenitis Suppurativa were approximately 0.9 million cases in the US, which are expected to grow during the forecast period, i.e., 2025–2034.
In the 7MM, the US accounted for the highest number of diagnosed prevalent cases in 2024, contributing approximately 49% while Japan had the lowest share.
Among EU4 and the UK, Germany accounted for the highest number of Hidradenitis Suppurativa prevalent cases, while Spain accounted for the least prevalent cases.
In the US, approximately 25% of the patient share is attributed to males and 75% to females, whereas in Japan, approximately 70% patient share is attributed to males and around 30% to females.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of the Hidradenitis Suppurativa epidemiology, detailed assumptions, and rationale behind our approach are included in the report.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Hidradenitis Suppurativa Report Insights
Patient population
Prevalence pattern
Diagnosis rate
Country wise epidemiology distribution
Hidradenitis Suppurativa Report Key Strengths
Ten years forecast
The 7MM coverage
Hidradenitis suppurativa epidemiology segmentation
Hidradenitis Suppurativa Report Assessment
Epidemiology segmentation
Current diagnostic practices
Key Questions
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of hidradenitis suppurativa? What will be the growth opportunities across the 7MM with respect to the patient population of hidradenitis suppurativa?
What is the historical and forecasted hidradenitis suppurativa patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
At what CAGR is the population expected to grow in the 7MM during the study period (2020–2034)?
What will be the growth opportunities in the 7MM with respect to the patient population of hidradenitis suppurativa?
What will be the eligible patient pool for treatment out of all prevalent cases?
Reasons to Buy
The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the hidradenitis suppurativa market.
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis, current diagnosis rate, and treatment-eligible patient pool.
Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
In 2024, there were around 1.8 million diagnosed prevalent cases of hidradenitis suppurativa in the 7MM, and this number is expected to grow over the forecast period.
Low disease awareness and associated misdiagnoses and under-reporting by patients because of shame and embarrassment have contributed to substantial delays in diagnosis, reported to be between 7 and 10 years on average. The course of the disease is often unpredictable, which can be challenging for patients and healthcare professionals (HCPs) in managing hidradenitis suppurativa.
According to secondary research, the widely reported prevalence rate is 0.03-4 percent. This disparity could be explained by differences in research design (for example, prospective vs. retrospective studies or registry-based vs. self-reported questionnaire-based studies).
Many hidradenitis suppurativa patients are often misdiagnosed and not at all diagnosed. Based on the analysis it is estimated that only 25–30% of patients receive the diagnosis of hidradenitis suppurativa.
The Gender-specific analysis suggests that hidradenitis suppurativa is more prevalent in females than males in the US and Europe but in Japan, it is more prevalent in males than females.
Data suggests that of the diagnosed patient pool, roughly 40%–50% of the hidradenitis suppurativa patients have moderate-to-severe disease in the US.
According to DelveInsight’s analysis, the highest proportion of hidradenitis suppurativa prevalent pool was observed in the 30–39 age group among the 7MM.
According to Hurley’s classification, hidradenitis suppurativa can be classified into stages, i.e., Stage I, II, and III. The most prevalent cases are estimated to be at Stage I.
DelveInsight’s “Hidradenitis Suppurativa – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Hidradenitis Suppurativa, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Hidradenitis Suppurativa Disease Understanding
Hidradenitis Suppurativa Overview
Hidradenitis suppurativa is a complex dermatological disease characterized by recurrent painful nodules and suppuration in areas such as the axilla and groin. It is also known as acne inversa, and there is no biological or pathological test to facilitate diagnosis; its clinical features and chronicity can define it.
The underlying cause of hidradenitis suppurativa is unknown, but the condition probably results from genetic and environmental factors.
Hidradenitis Suppurativa Diagnosis
The diagnosis is primarily clinical, based on symptoms reported by the patient and signs observed by the physician. No pathognomonic test exists; a biopsy is rarely required, especially in well-developed lesions. Primary diagnosis of hidradenitis suppurativa involves identifying the disease and assessing its comorbidities.
Fulfillment of three criteria is necessary for the diagnosis of Hidradenitis suppurativa, which includes- typical lesions (deep-seated, painful nodules), characteristic distribution or typical anatomical predilection (i.e., axillae, groins, perineal and perianal regions, buttocks, infra-mammary and inter-mammary folds), and recurrence (Chronicity and recurrence of lesions). Arbitrarily, two recurrences over 6 months have been used as a qualifier for a diagnosis. All three criteria must be present for the definitive diagnosis. Smoking is a significant association, and cessation is important for disease control. Approximately one-third of patients with hidradenitis suppurativa have a family history of the disease.
Further details related to diagnosis are provided in the reported
Hidradenitis Suppurativa Epidemiology
As the market is derived using a patient-based model, the Hidradenitis Suppurativa epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of hidradenitis suppurativa, total diagnosed prevalent cases of hidradenitis suppurativa, gender-specific diagnosed prevalent cases of hidradenitis suppurativa, age-specific diagnosed prevalent cases of hidradenitis suppurativa, stage-specific diagnosed prevalent cases of hidradenitis suppurativa and total treated diagnosed prevalent cases of hidradenitis suppurativa in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.
The total prevalent cases of hidradenitis suppurativa in the 7MM comprised approximately 6.3 million cases in 2024 and are projected to increase during the forecast period.
In 2024, the total diagnosed prevalent cases of Hidradenitis Suppurativa were approximately 0.9 million cases in the US, which are expected to grow during the forecast period, i.e., 2025–2034.
In the 7MM, the US accounted for the highest number of diagnosed prevalent cases in 2024, contributing approximately 49% while Japan had the lowest share.
Among EU4 and the UK, Germany accounted for the highest number of Hidradenitis Suppurativa prevalent cases, while Spain accounted for the least prevalent cases.
In the US, approximately 25% of the patient share is attributed to males and 75% to females, whereas in Japan, approximately 70% patient share is attributed to males and around 30% to females.
Scope of the Report
The report covers a segment of key events, an executive summary, and a descriptive overview of Hidradenitis Suppurativa, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of the Hidradenitis Suppurativa epidemiology, detailed assumptions, and rationale behind our approach are included in the report.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Hidradenitis Suppurativa Report Insights
Patient population
Prevalence pattern
Diagnosis rate
Country wise epidemiology distribution
Hidradenitis Suppurativa Report Key Strengths
Ten years forecast
The 7MM coverage
Hidradenitis suppurativa epidemiology segmentation
Hidradenitis Suppurativa Report Assessment
Epidemiology segmentation
Current diagnostic practices
Key Questions
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of hidradenitis suppurativa? What will be the growth opportunities across the 7MM with respect to the patient population of hidradenitis suppurativa?
What is the historical and forecasted hidradenitis suppurativa patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
At what CAGR is the population expected to grow in the 7MM during the study period (2020–2034)?
What will be the growth opportunities in the 7MM with respect to the patient population of hidradenitis suppurativa?
What will be the eligible patient pool for treatment out of all prevalent cases?
Reasons to Buy
The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the hidradenitis suppurativa market.
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis, current diagnosis rate, and treatment-eligible patient pool.
Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Table of Contents
103 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary of Hidradenitis Suppurativa
- 4. Epidemiology Methodology OF Hidradenitis Suppurativa
- 4.1. Patient Share (%) Distribution of Hidradenitis Suppurativa in 2020
- 4.2. Patient Share (%) Distribution of Hidradenitis Suppurativa in 2034
- 5. Disease Overview: Hidradenitis Suppurativa
- 5.1. Introduction
- 5.2. Causes and Symptoms of Hidradenitis Suppurativa
- 5.3. Classification and Severity Assessment of Hidradenitis Suppurativa
- 5.3.1. Hurley Stages of hidradenitis suppurativa
- 5.3.2. Modified Sartorius Score (MSS) of hidradenitis suppurativa
- 5.3.3. Physician Global Assessment of Hidradenitis Suppurativa
- 5.3.4. Specific Severity Index of Hidradenitis Suppurativa (HSSI)
- 5.4. Pathophysiology of Hidradenitis Suppurativa
- 5.5. Genetic Basis of Hidradenitis Suppurativa
- 5.6. Diagnosis of Hidradenitis Suppurativa
- 5.6.1. Differential Diagnosis
- 5.7. Biomarkers of Hidradenitis Suppurativa
- 5.8. Risk Factors and Complications
- 5.9. Comorbidities
- 6. Epidemiology and Patient Population
- 6.1. Key Findings
- 6.2. Assumptions and Rationale: 7MM
- 6.3. Total Prevalent Cases of Hidradenitis Suppurativa in the 7MM
- 6.4. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the 7MM
- 6.5. The United States
- 6.5.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the US
- 6.5.2. Gender-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the US
- 6.5.3. Age-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the US
- 6.5.4. Stage-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the US
- 6.5.5. Total Treated Diagnosed Prevalent Cases of Hidradenitis Suppurativa in the US
- 6.6. EU4 and the UK
- 6.6.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK
- 6.6.2. Gender-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK
- 6.6.3. Age-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK
- 6.6.4. Stage-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK
- 6.6.5. Total Treated Diagnosed Prevalent Cases of Hidradenitis Suppurativa in EU4 and the UK
- 6.7. Japan
- 6.7.1. Total Diagnosed Prevalent Cases of Hidradenitis Suppurativa in Japan
- 6.7.2. Gender-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in Japan
- 6.7.3. Age-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in Japan
- 6.7.4. Stage-specific Diagnosed Prevalent Cases of Hidradenitis Suppurativa in Japan
- 6.7.5. Total Treated Diagnosed Prevalent Cases of Hidradenitis Suppurativa in Japan
- 7. Appendix
- 7.1. Bibliography
- 7.2. Report Methodology
- 8. DelveInsight Capabilities
- 9. Disclaimer
- 10. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
